AAAAAA

   
Results: 1-25 | 26-31
Results: 1-25/31
Phase I-II vinorelbine (Navelbine((R))) by continuous infusion in patientswith metastatic breast cancer: Cumulative toxicities limit dose escalation
Authors: Ibrahim, NK Valero, V Rahman, Z Theriault, RL Walters, RS Buzdar, AU Booser, DJ Holmes, FA Murray, DJ Willey, J Bast, R Hortobagyi, GN
Citation: Nk. Ibrahim et al., Phase I-II vinorelbine (Navelbine((R))) by continuous infusion in patientswith metastatic breast cancer: Cumulative toxicities limit dose escalation, CANCER INV, 19(5), 2001, pp. 459-466
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer
Authors: Rivera, E Valero, V Syrewicz, L Rahman, Z Esteva, FL Theriault, RL Rosales, MM Booser, D Murray, JL Bast, RC Hortobagyi, GN
Citation: E. Rivera et al., Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer, J CL ONCOL, 19(6), 2001, pp. 1716-1722
Long-term results of combined-modality therapy for locally advanced breastcancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience
Authors: Brito, RA Valero, V Buzdar, AU Booser, DJ Ames, F Strom, E Ross, M Theriault, RL Frye, D Kau, SW Asmar, L McNeese, M Singletary, SE Hortobagyi, GN
Citation: Ra. Brito et al., Long-term results of combined-modality therapy for locally advanced breastcancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience, J CL ONCOL, 19(3), 2001, pp. 628-633
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial
Authors: Hortobagyi, GN Ueno, NT Xia, WY Zhang, S Wolf, JK Putnam, JB Weiden, PL Willey, JS Carey, M Branham, DL Payne, JY Tucker, SD Bartholomeusz, C Kilbourn, RG De Jager, RL Sneige, N Katz, RL Anklesaria, P Ibrahim, NK Murray, JL Theriault, RL Valero, V Gershenson, DM Bevers, MW Huang, L Lopez-Berestein, G Hung, MC
Citation: Gn. Hortobagyi et al., Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial, J CL ONCOL, 19(14), 2001, pp. 3422-3433
Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer
Authors: Wang, MLH Yung, WKA Royce, ME Schomer, DF Theriault, RL
Citation: Mlh. Wang et al., Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer, AM J CL ONC, 24(4), 2001, pp. 421-424
The evolving role of bisphosphonates
Authors: Theriault, RL Hortobagyi, GN
Citation: Rl. Theriault et Gn. Hortobagyi, The evolving role of bisphosphonates, SEMIN ONCOL, 28(3), 2001, pp. 284-290
Female patients with breast carcinoma age 30 years and younger have a poorprognosis - The M. D. Anderson Cancer Center Experience
Authors: Xiong, QH Valero, V Kau, V Kau, SW Taylor, S Smith, TL Smith, TL Buzdar, AU Hortobagyi, GN Theriault, RL
Citation: Qh. Xiong et al., Female patients with breast carcinoma age 30 years and younger have a poorprognosis - The M. D. Anderson Cancer Center Experience, CANCER, 92(10), 2001, pp. 2523-2528
Special clinical situations in patients with breast cancer
Authors: Gwyn, KM Theriault, RL
Citation: Km. Gwyn et Rl. Theriault, Special clinical situations in patients with breast cancer, MDA CANC CA, 2001, pp. 406-429
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma
Authors: Hortobagyi, GN Buzdar, AU Theriault, RL Valero, V Frye, D Booser, DJ Holmes, FA Giralt, S Khouri, I Andersson, B Gajewski, JL Rondon, G Smith, TL Singletary, SE Ames, FC Sneige, N Strom, EA McNeese, MD Deisseroth, AB Champlin, RE
Citation: Gn. Hortobagyi et al., Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma, J NAT CANC, 92(3), 2000, pp. 225-233
Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients:The M.D. Anderson experience, with long-term follow-up
Authors: Ibrahim, NK Buzdar, AU Asmar, L Theriault, RL Hortobagyi, GN
Citation: Nk. Ibrahim et al., Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients:The M.D. Anderson experience, with long-term follow-up, ANN ONCOL, 11(12), 2000, pp. 1597-1601
Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer
Authors: Ibrahim, NK Valero, V Theriault, RL Willey, J Walters, RS Buzdar, AU Booser, DJ Hortobagyi, GN
Citation: Nk. Ibrahim et al., Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer, AM J CL ONC, 23(2), 2000, pp. 117-121
Synchronous primary cancers of the breast and cervix: Planning multidisciplinary primary treatment
Authors: Verstovsek, S Verschraegen, CF Edwards, CL Malpica, A Kavanagh, JJ Ross, MI Strom, EA Jhingran, A Theriault, RL Kudelka, AP
Citation: S. Verstovsek et al., Synchronous primary cancers of the breast and cervix: Planning multidisciplinary primary treatment, AM J CL ONC, 23(1), 2000, pp. 99-103
High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study
Authors: Weiss, RB Rifkin, RM Stewart, FM Theriault, RL Williams, LA Herman, AA Beveridge, RA
Citation: Rb. Weiss et al., High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study, LANCET, 355(9208), 2000, pp. 999-1003
Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy
Authors: Rivera, E Holmes, FA Frye, D Valero, V Theriault, RL Booser, D Walters, R Buzdar, AU Dhingra, K Fraschini, G Hortobagyi, GN
Citation: E. Rivera et al., Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy, CANCER, 89(11), 2000, pp. 2195-2201
Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy
Authors: Hoff, PM Valero, V Buzdar, AU Singletary, SE Theriault, RL Booser, D Asmar, L Frye, D McNeese, MD Hortobagyi, GN
Citation: Pm. Hoff et al., Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy, CANCER, 88(9), 2000, pp. 2054-2060
Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases - Long term follow-up of two randomized, placebo-controlled trials
Authors: Lipton, A Theriault, RL Hortobagyi, GN Simeone, J Knight, RD Mellars, K Reitsma, DJ Heffernan, M Seaman, JJ
Citation: A. Lipton et al., Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases - Long term follow-up of two randomized, placebo-controlled trials, CANCER, 88(5), 2000, pp. 1082-1090
Treatment of bone metastases: Chemo- and hormone therapy
Authors: Theriault, RL Hortobagyi, GN
Citation: Rl. Theriault et Gn. Hortobagyi, Treatment of bone metastases: Chemo- and hormone therapy, TUMOR BONE DISEASES AND OSTEOPOROSIS IN CANCER PATIENTS, 2000, pp. 227-243
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results
Authors: Holmes, FA Valero, V Walters, RS Theriault, RL Booser, DJ Gibbs, H Fraschini, G Buzdar, AU Willey, J Frye, D Asmar, L Hortobagyi, GN
Citation: Fa. Holmes et al., Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results, ANN ONCOL, 10(4), 1999, pp. 403-411
Update: NCCN practice guidelines for the treatment of breast cancer
Authors: Carlson, RW Anderson, BO Bensinger, W Cox, C Davidson, NE Edge, SB Farrar, WB Goldstein, LJ Gradishar, WJ Lichter, AS Mccormick, B Nabell, LM Reed, EC Silver, SM Smith, MLP Somlo, G Theriault, RL Winer, EP
Citation: Rw. Carlson et al., Update: NCCN practice guidelines for the treatment of breast cancer, ONCOLOGY-NY, 13(11A), 1999, pp. 187-212
Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, andfluorouracil as first-line therapy in patients with metastatic breast cancer
Authors: Valero, V Buzdar, AU Theriault, RL Azarnia, N Fonseca, GA Willey, J Ewer, M Walters, RS Mackay, B Podoloff, D Booser, D Lee, LW Hortobagyi, GN
Citation: V. Valero et al., Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, andfluorouracil as first-line therapy in patients with metastatic breast cancer, J CL ONCOL, 17(5), 1999, pp. 1425-1434
Estrogen replacement therapy after localized breast cancer: Clinical outcome of 319 women followed prospectively
Authors: Vassilopoulou-Sellin, R Asmar, L Hortobagyi, GN Klein, MJ McNeese, M Singletary, SE Theriault, RL
Citation: R. Vassilopoulou-sellin et al., Estrogen replacement therapy after localized breast cancer: Clinical outcome of 319 women followed prospectively, J CL ONCOL, 17(5), 1999, pp. 1482-1487
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial
Authors: Theriault, RL Lipton, A Hortobagyi, GN Leff, R Gluck, S Stewart, JF Costello, S Kennedy, I Simeone, J Seaman, JJ Knight, RD Mellars, K Heffernan, M Reitsma, DJ
Citation: Rl. Theriault et al., Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial, J CL ONCOL, 17(3), 1999, pp. 846-854
Management of breast cancer during pregnancy using a standardized protocol
Authors: Berry, DL Theriault, RL Holmes, FA Parisi, VM Booser, DJ Singletary, SE Buzdar, AU Hortobagyi, GN
Citation: Dl. Berry et al., Management of breast cancer during pregnancy using a standardized protocol, J CL ONCOL, 17(3), 1999, pp. 855-861
Clinical course of breast cancer patients with complete pathologic primarytumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
Authors: Kuerer, HM Newman, LA Smith, TL Ames, FC Hunt, KK Dhingra, K Theriault, RL Singh, G Binkley, SM Sneige, N Buchholz, TA Ross, MI McNeese, MD Buzdar, AU Hortobagyi, GN Singletary, SE
Citation: Hm. Kuerer et al., Clinical course of breast cancer patients with complete pathologic primarytumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy, J CL ONCOL, 17(2), 1999, pp. 460-469
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer
Authors: Buzdar, AU Singletary, SE Theriault, RL Booser, DJ Valero, V Ibrahim, N Smith, TL Asmar, L Frye, D Manuel, N Kau, SW McNeese, M Strom, E Hunt, K Ames, F Hortobagyi, GN
Citation: Au. Buzdar et al., Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer, J CL ONCOL, 17(11), 1999, pp. 3412-3417
Risultati: 1-25 | 26-31